Many Faces of Renin-angiotensin System - Focus on Eye by Holappa, Mervi et al.
Send Orders for Reprints to reprints@benthamscience.ae
122 The Open Ophthalmology Journal, 2017, 11, 122-142
1874-3641/17 2017  Bentham Open
The Open Ophthalmology Journal
Content list available at: www.benthamopen.com/TOOPHTJ/
DOI: 10.2174/1874364101711010122
REVIEW ARTICLE
Many Faces of Renin-angiotensin System - Focus on Eye
Mervi Holappa1, Heikki Vapaatalo2 and Anu Vaajanen3,4,*
1 BioMediTech, University of Tampere, Tampere, Finland
2Medical Faculty, Department of Pharmacology, University of Helsinki, 00014 Helsinki, Finland
3Department of Ophthalmology, Tampere University Hospital, Tampere, Finland
4SILK, Department of Ophthalmology, School of Medicine, University of Tampere, Tampere, Finland
Received: April 16, 2017 Revised: May 17, 2017 Accepted: May 25, 2017
Abstract: The renin-angiotensin system (RAS), that is known for its role in the regulation of blood pressure as well as in fluid and
electrolyte homeostasis, comprises dozens of angiotensin peptides and peptidases and at least six receptors. Six central components
constitute the two main axes of the RAS cascade. Angiotensin (1-7), an angiotensin converting enzyme 2 and Mas receptor axis
(ACE2-Ang(1-7)-MasR) counterbalances the harmful effects of the angiotensin II, angiotensin converting enzyme 1 and angiotensin
II  type 1 receptor axis (ACE1-AngII-AT1R) Whereas systemic RAS is an important factor in blood pressure regulation,  tissue-
specific regulatory system, responsible for long term regional changes, that has been found in various organs. In other words, RAS is
not only endocrine but also complicated autocrine system. The human eye has its own intraocular RAS that is present e.g. in the
structures involved in aqueous humor dynamics. Local RAS may thus be a target in the development of new anti-glaucomatous
drugs. In this review, we first describe the systemic RAS cascade and then the local ocular RAS especially in the anterior part of the
eye.
Keywords: ACE1, ACE2, Angiotensin II, Angiotensin (1-7), Eye, Glaucoma, Intraocular pressure, Mas receptor, Renin-angiotensin
system.
INTRODUCTION
Glaucoma, known for its destructive effects on the optic nerve axons and retinal ganglion cells, is one of the leading
causes of blindness worldwide. In the next three years, approximately 80 million people around the world are predicted
to  be  diagnosed  with  glaucoma  [1].  This  number  is  likely  to  be  even  higher  due  to  the  fact  that  glaucoma  can  be
asymptomatic for a long time which makes it difficult to detect until it is severe [2, 3]. Glaucoma is a multifactorial
optic  neuropathy that  can be roughly divided into two categories:  open-angle glaucoma (POAG) and angle-closure
glaucoma, both of which can cause visual field defects and irreversible vision loss [4 - 10].
While  many  genetic  and  biological  risk  factors  have  been  identified,  such  as  age,  race  and  diabetes,  the  most
fundamental reason why a patient is diagnosed with glaucoma is increased intraocular pressure (IOP) [6, 10 - 13]. The
exact  underlying  mechanism  for  glaucoma  development  is  still  poorly  known  which  makes  it  difficult  to  develop
effective therapies for this destructive disease [14, 15]. As of today, the only treatment demonstrated to be effective to
reduce disease progress is to lower IOP [16, 17]. That is to say, decrease of IOP by 30% reduces disease progress [18,
19]. In addition to the classical RAS that regulates blood pressure (BP), fluid volume as well as electrolyte balance and
is also involved in inflammation, local tissue-specific RA-systems have been described in numerous organs including
the human eye [20 - 24]. While the pathological mechanisms at molecular level are not yet well understood, local ocular
RAS seems to have a role in ocular pathology and it has been associated to glaucoma and other eye disorders such as
diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinopathy of prematurity (ROP) [22, 25]. In
this  review,  we  describe  the  local  ocular  RAS  cascade  and concentrate  on its  potential role  in the  regulation  of
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IOP while keeping the focus on the anterior part  of the eye.  A comprehensive survey of literature on PubMed was
performed to collect the literature and eventually 258 articles were chosen based on their relevance. The following
keywords  were  used  and  combined  to  narrow down the  literature:  IOP (41729),  RAS (29132),  tissue  RAS (6080),
angiotensin (116858), angiotensin I (8316), angiotensin II (59230), angiotensin (1-7) (1278), angiotensin (1-9) (73),
angiotensin (3-4) (10) angiotensin converting enzyme 1 (238) and -2 (1453), Mas receptor (445), angiotensin receptor
(17975), eye disease (5611), glaucoma (59565), diabetic retinopathy (DR) (26740), retinopathy of prematurity (ROP)
(6638) and age-related macular degeneration (AMD) (13303).
RENIN-ANGIOTENSIN SYSTEM
Circulating Ras
The renin-angiotensin system is one of the oldest and most studied peptide cascades known today. The research
concentrating  on  RAS started,  in  1898,  in  Finland  when  Robert  Tigerstedt  and  Per  Bergman  identified  a  renal  BP
elevating substance: renin [20, 26, 27]. Over 40 years later, more components of the RAS cascade were identified, one
being the angiotensin peptide, first named as angiotonin, that Braun-Menéndez and Page reported to be formed from
angiotensinogen  by  renin,  an  enzyme  originated  in  the  kidney  [28  -  30].  1970  was  an  important  year  in  the  RAS
research  as  its  role  in  BP  and  fluid  balance  regulator  was  understood  which  led  to  the  development  of  the  first
antihypertensive medications such as captopril that blocks the formation of Ang II by inhibiting ACE1 [20, 28]. Later
more antihypertensive drugs were designed and developed, one of which was Ang II type 1 receptor blocker (ARB) that
blocks the vasoconstrictive effects of Ang II through its main receptor [31].
Multiple peptides, enzymes and receptors have been identified since the first clue of the existence of RAS. One of
the important and fairly recent findings was the identification of a new receptor type: MasR whose activities, such as
vasodilatation, antifibrosis and antiproliferation, are opposite to those of angiotensin II type 1 receptor (AT1R). This
discovery led to the division of RAS into two central axes: ACE1-Ang II-AT1R and ACE2-Ang(1-7)-MasR giving
antihypertensive drug development new angles to focus on [32 - 34] as chronic imbalances of these main axes can
potentially lead to pathological events of e.g. renal, cardiovascular and central nervous system [35]. In time, RAS has
truly  evolved  from simple  linear  pathway,  having  only  one  known  substrate,  two  proteases,  two  peptides  and  one
receptor, into a complex cascade consisting of multiple mediators, functionally versatile enzymes and various receptors
that are activated by several angiotensin peptides [36 - 40]. Figure 1 shows the full extent of the RAS cascade known
today.
Fig. (1). The renin-angiotensin system. The two main axes of RAS are highlighted with colors. ACE2-Ang(1-7)-MasR axis (red
lines) counterbalances the harmful effects of the ACE1-Ang II-AT1R axis (blue lines). ACE1: Angiotensin-converting enzyme 1;
ACE2: Angiotensin-converting enzyme related carboxypeptidase; Ang I, II, III, IV: Angiotensin I, II, III, IV; Ang A: Angiotensin A;
AT1R, -2R, -4R: Angiotensin II type 1, -2, -4 receptor; AP: Aminopeptidase (-A, -N, -M, -B); B1/B2: Bradykinin receptors; CAGE:
Chymostatin-sensitive Ang II generating enzyme; CP: Carboxypeptidase; EP: Endopeptidase; Mas receptor: Ang(1-7) receptor type;
NEP: Neprilysin; PEP: Prolyl-endopeptidase; PCP: Prolyl-carboxypeptidase; tPA: Tissue-type plasminogen activator. In angiotensin
peptides the numbers in parenthesis refers to the numbers of amino acid residues. The figure is updated from Vaajanen et al. [41].
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The classical RAS cascade starts with highly specific aspartyl protease renin that cleaves the peptide bond between
Leu10 and Val11 at the amino terminus of angiotensinogen (AGT), a 225 amino acids long α-glycoprotein, to form
angiotensin I (Ang I) [28, 42, 43]. AGT is mainly synthesized and released from liver but other organs such as heart,
kidney  and  adipose  tissue  can  also  produce  it  [44].  Inflammation,  insulin  and  estrogens  among  other  things  can
stimulate the synthesis of AGT [42]. Renin is mainly synthesized in kidney as an inactive prorenin that is activated by
either cathepsin B or proconvertase and secreted from the juxtaglomerular apparatus [28, 42, 43] in response to either
decreased arterial BP, decreased sodium levels or increased activity of sympathetic nervous system [45 - 47]. Both renin
and prorenin can bind to (pro)renin receptor ((P)RR) and thus mediate vasoconstrictive effects [42, 48].
Ang I, a weak prohormone and vasoconstrictor can be further cleaved to form Ang II. Different enzymes can form
Ang II from Ang I: e.g. ACE1, tonin [49], trypsin [50], kallikrein [51], cathepsin G [52] and chymase [53 - 55]. ACE1
is present in many tissues as well as in biological fluids e.g. in plasma [56 - 58]. In order to work, ACE1 needs Zn2+ in
complex with activated water molecule in its active site [59] and chloride to improve substrate binding [60]. This main
enzyme acting on Ang I, removes two amino acids (His-Leu) from the carboxyl terminus of Ang I to form one of the
central  peptides  of  RAS  cascade:  Ang  II.  In  addition  to  being  an  important  enzyme  in  RAS,  ACE1  also  acts  in
kallikrain-kinin  system [42,  45].  Other  enzymes  mentioned  above  are  regarded  as  alternative  pathways  for  Ang  II
generation [61 - 63] which are important in physiological and pathophysiological conditions [64, 65]. However, these
pathways are not discussed further in this review.
In  1940,  Ang  II  an  octapeptide  also  known  as  Ang  (1-8)  was  first  isolated  and  characterized  as  a  potent
vasoconstrictor that raises BP and regulates e.g. electrolyte balance, vascular tone and thirst [29, 30, 43]. It stimulates
the  release  of  aldosterone  and  vasopressin  and  exerts  its  harmful  actions,  such  as  vasoconstriction,  fibrosis  and
inflammation via G-protein coupled AT1R [42, 43, 66 - 68]. Furthermore, Ang II can also activate angiotensin II type 2
receptors (AT2R) whose activities are thought to oppose those of AT1R [31, 42, 43]. AT2Rs are regarded as protective
receptors as they may elicit vasodilatory, antihypertensive, proapoptotic as well as antiproliferative effects [53, 69] and
as they can bind directly to AT1R thus inhibiting signaling through it [31]. ACE inhibitors are used as antihypertensive
medications as they oppose the harmful effects of Ang II via AT1R by blocking the conversation of Ang I to Ang II by
ACE1 thus elevating the levels of Ang(1-7) [42, 43].
Angiotensin II can then be further cleaved by ACE1 or aminopeptidase A to generate angiotensin III (Ang III) or by
aminopeptidase N to form angiotensin IV (Ang IV) [20, 28, 42, 43]. Ang IV can also be generated from Ang III by
aminopeptidases  N,  M and B [28,  43].  Ang III  exerts  its  vasoconstrictive  actions  via  the  same receptors  as  Ang II
(higher affinity to AT2R) whereas Ang IV prefers angiotensin II type 4 receptors (AT4R) which are related to cognitive
functions and proliferative effects and which are found e.g. in brain, lung and kidney [20, 70, 71]. Ang IV can also elicit
its biological effects, including renal vasodilatation, hypertrophy and regulation of cell growth, through activation of
AT1R [72].
Cleavage of one amino acid residue (Phe) from carboxyl terminus of Ang I by ACE2 [73], carboxypeptidase A or
cathepsin A [74, 75] generate angiotensin (1-9) (Ang(1-9)) whose main biological functions are to release arachidonic
acid,  promote nitric oxide formation and increase bradykinin activity [74].  Ang(1-9) may also reduce BP, decrease
hypertension [76] and possibly play a role in inhibition of platelet function [77]. The formation of Ang(1-9) is thought
to  be  dependent  on  ACE2  activity  [73,  78]  and  it  has  been  suggested  that  Ang(1-9)  could  mediate  its  actions  by
activating the AT2 receptors [76, 79]. ACE2 (42% sequence identity to ACE1) was first cloned in 2000 and has since
been identified in multiple organs such as kidney, heart, brain, liver and lung [42, 73, 80 - 82]. ACE2 has been shown to
convert Ang I to Ang(1-9) [73] and most importantly to form Ang(1-7) from Ang II [42, 80, 83 - 85]. This enzyme has
zinc metallopeptidase consensus sequence (HEXXH) in its active site and like its homologue ACE2 activity is also
regulated by the presence of chloride ions [42]. ACE2 cleaves only one amino acid residue from Ang II thus enhancing
Ang(1-7)  formation  and  leaving  less  substrate  to  ACE1  to  act  on  [42,  82].  Furthermore,  ACE  inhibitors  used  as
antihypertensive medications do not block ACE2 activity making this enzyme together with Ang(1-7) and MasR the
focus of the research regarding RAS and cardiovascular drug development [80, 86].
Ang(1-7) that was first thought to be devoid of biological function can be generated from Ang II by ACE2, prolyl-
endopeptidase and prolyl-carboxypeptidase [20, 43, 80, 87] or from Ang(1-9) by ACE1 and NEP [83]. It can also be
metabolized  directly  from  Ang  I  or  from  prohormone  Ang(1-12)  bypassing  the  biosynthesis  of  Ang  II  [43,  87].
Moreover, Ang(1-7) can be further metabolized into smaller peptides such as angiotensin (1-5) or angiotensin (2-7)
[28].
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Ang(1-7) is known to have functions opposite to those of Ang II [43]. Although, Ang(1-7) may interact with AT1R
and AT2R [76, 79, 84, 86], this peptide elicits its vasodilating and antiproliferatory effects through activation of its
main receptor MasR [20, 42, 79, 84]. MasR is a G-protein coupled receptor [88] that was first described as a proto-
oncogene [89]. This receptor has been found e.g. in eye, central nervous system, kidney, heart and brain [88, 90 - 93]
and is known to act antagonistically to AT1R [53]. Due to its antiarrhythmogenic, antithrombogenic, growth-inhibitory
and vasoconstrictive inhibitory properties, Ang(1-7) is seen as a protective peptide that acts as a counterregulator within
RAS [38 - 40]. Interestingly, the association between Ang(1-7) and pathology of multiple diseases such as hypertension
[84, 86, 87, 94 - 98] and diabetic nephropathy [46, 99, 100] makes this peptide a potential target for drug development.
Interestingly,  in  addition  to  ACE2-Ang(1-7)-MasR  axis,  a  newly  described  member  of  RAS,  angiotensin(3-4)
(Ang(3-4)) counteracts the traditional ACE1-Ang II-AT1R pathway both systemically and locally[101]. Ang(3-4) has
antihypertensive effects that are mediated via AT2 receptors. This dipeptide is antiproliferative and vasodilating and it
inhibits ACE1. Furthermore, it is effective when administered orally, as it permeates intestinal cells relatively easily,
lowers Ang II and aldosterone levels in plasma and inhibits ACE1. Ang(3-4) levels are higher in healthy individuals
than in hypertensive patients [101]. All in all, it remains open what are the therapeutic possibilities of Ang(3-4) and its
potential functions in local RA-systems beyond renal tissue such as in eye.
In  addition  to  previously  mentioned  angiotensin  peptides  and  enzymes,  there  are  several  different  peptidases,
proteases and small peptides that are part of the RAS cascade but are not discussed in this review. However, all of these
enzymes and smaller angiotensin peptides are shown in Fig. (1). In addition, the kallikrein-kinin system that is also
shown in Figure 1 and that interacts with RAS is not discussed in detail in this review.
TISSUE RAS
Even  though  circulatory  RAS  has  many  important  roles  in  human  body,  various  organs  have  their  own  tissue
specific RA-systems that elicit long term changes and local effects such as growth, proliferation and protein synthesis at
organ level [20, 31, 64]. Ganten et al. 1971 were the first researchers to show that RAS is also an organ specific system
that has important regulatory roles at tissue level [102]. For example, heart, brain, intestine and even the human eye
have their own local RA-systems [6, 31, 43].
Later, local RA-systems were divided into two groups based on the origin of Ang II: extrinsic RAS gets its Ang II
from the circulation whereas intrinsic RAS synthesises its own Ang II locally [103]. Although some of the local RA-
systems depend on interactions with circulatory RAS to fully  operate,  in  many organs tissue RA-systems prefer  to
function independently [43]. Indeed local tissue-specific RA-systems can independently produce different components
of RAS thus proving that RAS is more than just an endocrine circulatory system and that it regulates more functions
than suggested earlier [6, 31, 43, 64].
Local  ocular  RAS has  been found partly  in  the  eye.  So far  all  of  the  central  components  of  RAS including the
components of the two main axes: ACE1-Ang II-AT1R and ACE2-Ang(1-7)-MasR have been identified in different eye
structures in various species [6, 9]. In the human eye, elements of the two main axes have been identified in retinal as
well  as  in  non-retinal  ocular  structures  [6,  93,  104].  Tables  (1  and 2)  summarize the localization of  RAS peptides,
enzymes and receptors in non-retinal ocular structures of the human eye.
Table 1. Renin-angiotensin system components in bulbar conjunctiva, cornea, trabecular meshwork, aqueous humor, iris,
ciliary body and non-pigmented ciliary epithelium, of the human eye.
RAS component Bulbar conjunctiva Cornea
Trabecular
meshwork
Aqueous humor Iris Ciliary body/NPE References
Prorenin x x x x x [24, 105 - 108]
Renin x x x x [105, 108]
AGT x x x x x [105, 109, 110]
ACE1 x x x x x x [104, 105, 110 - 116]
ACE2 x [104]
Ang I x x x [117, 118]
Ang II x x x x x x [111, 117 - 119]
Ang(1–7) x x x [93, 104]
(P)RR x x x x [105]
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RAS component Bulbar conjunctiva Cornea
Trabecular
meshwork
Aqueous humor Iris Ciliary body/NPE References
AT, unknown subtype x x [120, 121]
AT1R x x x x [105, 119, 122]
AT2R x x [119]
AT4R
MasR x x x [93]
Table  modified  and  updated  from  the  table  published  by  Holappa  et  al.  [123].  ACE1,  -2:  Angiotensin  converting  enzyme  1,  -2;  AGT:
Angiotensinogen; Ang I, -II: Angiotensin I, -II; Ang(1–7): Angiotensin (1–7); AT1R, -2R, -4R: Angiotensin II type 1, 2, 4 receptor; MasR: Mas
receptor; NPE: Non-pigmented ciliary epithelium; (P)RR: (pro)renin receptor; RAS: Renin-angiotensin system.
Table 2. Renin-angiotensin system components in lens, tears and lacrimal gland, vitreous, optic nerve head and sclera of the
human eye.
RAS component Lens Tears/Lacrimal gland Vitreous Optic nerve head Sclera References
Prorenin x x [24, 105, 107]
Renin x x [24, 105]
AGT x x [105, 110]
ACE1 x x x x [105, 112, 114, 115, 124 - 127]
ACE2
Ang I x [117]
Ang II x x [111, 119]
Ang(1–7)
(P)RR x [105]
AT, unknown subtype
AT1R x [119]
AT2R x [119]
AT4R
MasR
Table  modified  and  updated  from  the  table  published  by  Holappa  et  al.  [123].  ACE1,  -2:  Angiotensin  converting  enzyme  1,  -2;  AGT:
Angiotensinogen; Ang I, -II: Angiotensin I, -II; Ang(1–7): Angiotensin (1–7); AT1R, -2R, -4R: Angiotensin II type 1, 2, 4 receptor; MasR: Mas
receptor; (P)RR: (pro)renin receptor; RAS: Renin-angiotensin system.
Even  though  RAS  is  present  in  the  human  eye,  its  function  and  significance  in  ocular  pathophysiology  is  still
unknown. Whether angiotensin peptides found in the human eye originate partially from the blood compartment or are
synthesized locally has been the topic of the debate [117]. Circulating angiotensins e.g. Ang I and Ang II cannot pass
the blood-brain barrier and cannot reach the vitreous fluid when blood-retina barrier in the eye is intact [24, 117, 128,
129]. Moreover, in porcine eyes Ang I and Ang II levels are shown to be 5 to 100-fold higher than those found from
diffusion of blood [117] and in comparison to plasma ACE1 activity are higher in ocular structures of pig and rabbit
eyes [130, 131]. However, intraocular RAS may play a role in the regulation of IOP through its effects on AH dynamics
[9,  31].  Ang II  has been suggested to increase AH secretion via  AT1R [122].  Animal studies as well  as studies on
different patient groups indicate that systemic antihypertensive RAS-inhibiting medications such as ACE inhibitors
[103, 132, 133], ARBs [134 - 136] and renin inhibitors [137], reduce IOP. Moreover, intraocular RAS and its actions
have been linked to various eye diseases [6, 138].
EYE DISEASES AND LOCAL RAS
Glaucoma
Glaucoma is a multifactorial long-term neurodegenerative disorder which can be characterized by the non-apoptotic
and apoptotic death of retinal ganglion cells and the loss of retinal nerve fibers all of which lead to loss of visual field
[6, 7, 9, 10]. The death of retinal ganglion cells leads to increased IOP which is the most important risk factor for the
development of glaucoma and the only risk factor amenable to treatment [15, 138, 139]. Increased IOP can lead to
ischemia, mechanical impairment, oxidative stress and optic nerve inflammation [140]. However, not every patient with
high IOP develops glaucoma nor do all the glaucoma patients have increased IOP [15]. Several other risk factors such
as age, family history, diabetes, vascular dysfunction and systemic hypertension have also been linked to glaucoma [6, 9
(Table 1) contd.....
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- 11, 139, 141 - 144]. In addition to genetic and environmental factors, epigenetics also affect the signaling pathways
that are held responsible for glaucoma progression [145, 146].
IOP is maintained by a homeostatic balance between formation and outflow of AH. In the healthy human eye, the
flow of AH against resistance generates an IOP of about 15 mmHg (range 9-21 mmHg) [147 - 149]. Diurnal variation
of  IOP is  about  5  mmHg in  healthy  subjects.  Higher  IOP values  are  normally  measured  in  the  morning.  Transient
postural  IOP variations  can  be  even  twofold  e.g.  in  yoga  practioners  during  sirsasana,  headstand  posture  [150].  In
addition, physical exercise can influence ocular pressure [151, 152]. Typically aerobic exercise reduces IOP due to the
better ocular circulation [153] whereas anaerobic exercise elevates IOP due to the transient obstructed ocular circulation
[154]. The pressure is needed to maintain the optical and refractive properties of the eye [148, 149, 155]. One of the
other fundamental functions of IOP is to maintain the right shape of the eye [148, 155]. The normal AH formation rate
(2.5-2.8µL/min) is lower while sleeping (1.5µL/min) and can be reduced with ageing and in some systemic diseases
such as in diabetes [9, 139, 156].
AH is a mixture of different electrolytes, growth factors, proteins, amino acids, cytokines, inorganic and organic
solutes [157 - 161]. Circulating AH not only sustains and nourishes non-vascularized eye structures e.g. cornea and lens
but it also removes excretory products, transports neurotransmitters and enables mediators and inflammatory cells to
circulate in the eye [9, 156]. Ciliary body epithelial is the site of AH production [147]. Although two passive processes:
diffusion and ultrafiltration, that require no cellular activity nor energy [148], also participate on AH production [162],
active secretion accounts for 80-90% of the total AH formation [155, 156, 163]. Active and selective trans-cellular
transport of ions and molecules across the epithelium against concentration gradient requires energy that is generated by
hydrolysis of adenosine triphosphate (ATP) by Na+/K+ ATPase. Na+ and K+ activate ATP hydrolysis whereas different
molecules such as dinitrophenol and vanadate inhibit Na+/K+ ATPase [156, 164, 165]. Moreover, active transport of Na+
into the posterior chamber causes water flow from the stromal pool into the posterior chamber and two aquaporins
(AQP1 and  AQP4)  have  been  shown to  contribute  to  AH formation  [166,  167].  Other  ions  and  molecules  that  are
actively transported across the epithelium include Cl-, HCO3-, ascorbic acid and certain amino acids. However, active
transport of these components occur to a lesser extent [156, 166, 168 - 170]. After the production and secretion into the
posterior chamber, AH flows between the lens and the iris into the anterior chamber from where it will be disposed
[157, 171, 172].
From the anterior chamber, AH flows through the trabecular meshwork and the canal of Schlemm into the venous
blood system [147]. AH can exit the eye through the trabecular, the uveoscleral or the uveolymphatic pathways [139]
from which the first is pressure-dependent main route of drainage accounting for 90% of all AH outflow [9, 139, 173].
Aqueous humor flows through the porous trabecular meshwork passively when appropriate IOP level is reached and
AH gets filtered in the process [174]. The actin cytoskeleton and the adhesions of trabecular meshwork cells affect the
fluid  outflow  through  the  trabecular  meshwork  [175].  The  first  route  of  drainage  can  also  be  described  as  the
conventional pathway [176] which rate limiting step is the flow through the inner wall of Schelmm's canal [58]. From
Schelmm's canal dozens of collector channels connect with aqueous veins through which AH flows into the circulatory
system [177, 178].
In addition to trabecular pathway some AH exit the eye through the uveosscleral route [179]. In comparison to the
trabecular pathway the uveoscleral pathway is relatively independent of IOP and undergoes age-dependent changes
[173, 179]. The uveoscleral route of drainage can also be described as the unconventional pathway in which AH drains
through the ciliary muscle and exits through the supraciliary space across the anterior/posterior sclera into the choroidal
vessels and returns to systemic circulation [180, 181]. The rate limiting step in uveoscleral pathway is the flow through
the ciliary muscle [179].
The third route of drainage that is thought to work as a backup system is located in channels of the ciliary body
stroma  and  intestinal  space  between  ciliary  muscle  bundles  [182].  Other  minor  outflow  pathways  via  iris  vessels,
corneal  endothelium and anterior  vitreous body have also been described [183].  As IOP is  the net  sum of  aqueous
humor formation and outflow,  anti-glaucomatous treatments  aim to  lower  IOP by either  decreasing the rate  of  AH
formation  or  by  increasing  AH drainage  [184].  Lowering  IOP by  laser  therapy,  ocular  hypotensive  medications  or
surgical procedures is currently the only therapeutic tool to treat this devastating disease [6, 9, 10, 28].
Some studies have suggested that drugs affecting RAS by blocking its action e.g. ACE inhibitors [132, 133, 185]
and  ARBs  [134,  135]  might  be  potential  anti-glaucomatous  drugs  in  the  future.  Animal  studies  also  support  these
findings [103, 133, 135 - 137].  ACE inhibitors can affect IOP levels through their actions on AH dynamics.  These
128   The Open Ophthalmology Journal, 2017, Volume 11 Holappa et al.
inhibitors can decrease Ang II levels in AH, thus affecting the uveoscleral outflow [118, 186, 187], and slow down AH
formation by lowering blood flow in the ciliary body [188] which is the primary site of AH production. ACE inhibitors
also  act  through  kallikrein-kinin  system.  By  blocking  the  breakdown  of  bradykinin  these  inhibitors  support
prostaglandin  synthesis  which  in  turn  lowers  IOP  by  elevating  uveoscleral  outflow  [189  -  191].  By  preventing
bradykinin breakdown ACE inhibitors also cause vasodilatation as their actions lead to increased nitric oxide formation
by  endothelial  cells.  Both  prostaglandins  and  nitric  oxide  being  vasodilatory  also  inhibit  the  synthesis  of
vasoconstrictive  peptide  endothelin-1  [192  -  195].  In  addition,  ARBs  have  been  suggested  to  elevate  uveoscleral
outflow and slow down cell death of retinal ganglion cells [195, 196].
RAS components have also been identified in central structures of the eye responsible for AH formation and RAS
activity has been reported in cultured human non-pigmented ciliary epithelial cells [6, 120, 122]. Interestingly, Ang(1-7)
that acts via MasR and ACE2 activating diminazene aceturate (DIZE) have been reported to have positive effects on
glaucoma  by  decreasing  IOP  [41,  197,  198].  Indeed,  as  Ang(1-7)  actions  are  opposite  to  those  of  Ang  II,  this
heptapeptide is thought to have beneficial effects on the human body including the eye. Moreover, ACE2 activating
compounds are considered as novel pharmacotherapeutic agents [7, 41, 199 - 201].
Whereas Ang(1-7) and ACE2 activation are thought to have positive effects on IOP, Ang II has suggested to have
negative effects on the human eye even though some of the results are controversy. Ang II augments cell proliferation
in trabecular meshwork and increases collagen synthesis in vivo [187]. Intracamerally administered Ang II also lowers
uveoscleral outflow [41] whereas in cats intravenously administered Ang II decreases IOP [202]. Ang II can also act as
a secretagogue peptide in non-pigmented ciliary cells [122] as it promotes potassium ion channel activity through Ca2+
signaling [203] and causes higher cytoplasmic sodium concentration by activating Na+/H+ exchange [163]. Imbalances
in  sodium  handling  in  ciliary  and  renal  tubular  epithelium  might  explain  the  association  between  glaucoma  and
hypertension  [204].  On  the  other  hand,  defects  in  autoregulation  of  the  posterior  ciliary  circulation  [205]  and
microvascular damage affecting the optic nerve blood supply [206] both caused by hypertension could also explain the
coexistence of hypertension and glaucoma. Furthermore, hypotensive periods caused by antihypertensive medications
can also lead to injured optic nerve fibers [207].
Diabetic Retinopathy
Diabetic retinopathy (DR) is one of the most leading causes of blindness worldwide and one of the most common
microvascular complications of diabetes [208 - 210]. As diabetes becomes more and more common among adults, the
incidences of DR are predicted to rise dramatically. Nearly all patients with type 1 diabetes and almost 60% of patients
suffering  from  type  2  diabetes  show  some  signs  of  DR  later  in  diabetes  [211].  Many  factors  such  as  high  BP,
hyperglycemia, hyperlipidemia, age and oxidative stress play a role in the development of DR [212, 213]. The early
state  of  the  disease  is  described  as  non-proliferative  DR (NPDR)  in  which  microaneurysms  are  formed  due  to  the
weakened retinal blood vessels and blood-retinal barrier breaks down. After the formation of microaneurysms, fluid can
leak into retina causing swelling of the macula. Proliferative DR (PDR) is used of more serious and advanced form of
DR. In addition to the symptoms seen in NPDR, PDR also manifests blood vessel growth on the surface of the retina
and into the vitreous [209, 214, 215].
Studies have shown that RAS, especially Ang II mediated actions through AT1R, is involved in the progression of
DR [31,  52,  94,  216  -  218].  Over-expression  of  Ang II  and  prorenin  as  well  as  vascular  endothelial  growth  factor
(VEGF) exists in vitreous humor of individuals suffering from DR [24, 219 - 221]. Ang II promotes angiogenesis and
possibly  increases  the  risk  of  neovascularization  and  hyperpermeability  by  increasing  the  retinal  blood  vessel
permeability [219, 220, 222 - 225]. Furthermore, (P)RR has been linked to the development of DR through its direct
effects  on  expression  of  angiogenic  molecules  in  retinal  cells  [226  -  229].  RAS  involvement  in  angiogenesis  has
promoted research concentrating on the potential therapeutic role of RAS inhibitors in DR [230]. Blocking the RAS
cascade can actually slow down the progression of the disease [231 - 233] especially in normotensive patients [234]. In
patients with type 1 and type 2 diabetes, a link between decreased blood pressure and reduced DR progression has been
described [235, 236]. RAS inhibitors can reduce the risk of DR and possibly affect the progression of the disease in
diabetic patients [229]. In addition, ACE2 activation reduces retinal ganglion cell death in hyperglycemic rats [198].
Afterall, more basic research and randomized clinical trials are needed in the future to resolve the exact mechanism of
action of RAS compounds.
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Age-related Macular Degeneration
Age-related macular degeneration (AMD) is a major cause of irreversible vision loss among aged population. This
devastating disease is the reason why 8.7% of people worldwide suffer from blindness [237]. Whereas dry AMD is
characterized with the significant loss of photoreceptors leading to the loss of central vision, wet form of AMD causes
choroidal neovascularization in which pathologically grown blood vessels penetrate Bruch's membrane and populate
retina. 90% of AMD cases are diagnosed as dry form of AMD. Interestingly, in addition to many risk factors such as
old age, smoking, systemic hypertension as well as environmental and genetic factors imbalances in RAS cascade have
also been connected to the development of AMD [6, 22, 208, 238 - 241].
Circulating  RAS is  known for  its  role  as  the  regulator  of  BP and defects  in  RAS cascade  can  lead  to  systemic
hypertension  which  in  turn  raises  the  risk  of  developing  AMD.  Furthermore,  Ang  II  modulates  retinal  pigment
epithelium which suggests that impairment in RAS regulation might affect the function of retinal pigment epithelium as
well  as  the  viability  of  photoreceptors.  Ang  II  affects  retinal  angiogenesis  which  in  turn  suggests  that  this
vasoconstrictive octapeptide might also be involved in choroidal neovascularisation [6, 238]. The activation of two
types  of  RAS receptors:  AT1R and  (P)RR have  also  been  linked  to  the  development  of  AMD [242,  243].  Animal
studies have shown that losartan an AT1R antagonist [244], ARBs [245], ACE inhibitors [239] and (P)RR inhibitors
[243]  have  positive  effects  on  AMD as  these  compounds  can  reduce  choroidal  neovascularization  by  suppressing
inflammatory  agents.  As  of  today,  no  effective  therapies  are  available  for  treatment  of  dry  AMD [246].  However,
understanding the role of RAS in the development of AMD might help us manage and slow down the progression of
this disease [138, 247].
Retinopathy of Prematurity
Whereas  AMD  affects  elderly  people,  retinopathy  of  prematurity  (ROP)  is  an  eye  disease  that  only  affects
premature newborns (born <32 weeks) and can lead to permanent vision loss [25, 238]. The main risk factors identified
for development of ROP are lower gestational age and low birth weight (<1.5 kg). In industrialized countries, roughly
two-thirds of newborns with birth weight less than 1.25 kg manifest some signs of ROP. All the risk factors identified
for this disease correlate with retinal immaturity at birth [25, 248]. ROP can be characterized as neovascular disease in
which retinal neovascularisation leads to several complications such as macula dragging, tractional retinal detachment
and vitral haemorrhage [238]. When a premature newborn is brought into a high oxygen environment, the growth of
retinal blood vessels that expand from the optic nerve halts. After oxygen conditions are normalized, the inner retinal
vasculature fails to regain the normal growth which in turn creates an avascular area and leads to neovascularisation,
epiretinal angiogenesis and possibly loss of vision field [249]. Today, laser photocoagulation and intravitreal injections
of bevacizumab or pegaptanib are used as therapeutic tools to manage ROP [25, 250, 251].
Interestingly, studies have shown that newborns that are suffering from ROP have had increased levels of serum
prorenin [252], ocular renin [253, 254] as well as increased AT1R and AT2R expression [253]. Moreover, studies using
animal  models  with  oxygen  induced  retinopathy  have  shown that  ACE inhibitors  and  AT1R antagonist  treatments
during the normal air conditions can reduce pathological angiogenesis in retina [253, 255 - 257]. However, the effects
of treating retinal angiogenesis with AT2R antagonist and the possible role of AT2R in retinal vascular pathology are
still uncertain [223, 254, 256, 258]. Nath et al. studied RAS involvement in ROP in infant patients (n=44) suffering
from ROP as well as in rats with oxygen induced retinopathy. They found significantly higher levels of AGT, ACE1
and Ang II,  in vitreous humor of infants suffering from ROP compared to healthy controls.  Renin levels were also
increased  but  the  difference  was  found  to  be  statistically  not  significant.  In  animal  studies  up-regulated  mRNA
expressions  for  renin,  AGT,  ACE1  and  AT1R  were  found  in  retina  of  the  rats  suffering  from  oxygen  induced
retinopathy. Furthermore, ACE inhibitor (lisinopril) and ARB (telmisartan) were shown to suppress the over-activation
induced vascular and retinal functional changes in ROP [25]. However, further research is needed to understand the
involvement of RAS in the development and treatment of ROP.
CONCLUSION
Interestingly, in addition to circulating RAS that is involved in BP regulation and inflammation, local tissue specific
RAS has been identified in many organs of the human body including the eye. It has been detected in various parts of
the eye even in the structures involved in aqueous humor formation and outflow. These intriguing observations should
promote  more  research  concentrating  on  the  possible  role  of  local  RAS in  aqueous  humor  dynamics  and  thus  IOP
regulation.  However,  factors  such  as  retinal  ganglion  cell  death  due  to  other  reasons  than  pressure  might  also  be
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involved in glaucoma progression. Identification of the second counter-regulating axis of RAS (ACE2-Ang(1-7)-MasR)
has already brought new opportunities into light, and compounds affecting Ang(1-7) synthesis as well as MasR and
ACE2 activity offer new and exciting possibilities for ocular pharmacology in the future.
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